Last updated: February 28, 2026
What Are the Patent’s Defined Boundaries?
European Patent EP1819700 pertains to a pharmaceutical invention with a focus on specific compounds, formulations, or methods designed for therapeutic use. Its scope relies heavily on the claims, which define the extent of legal protection.
Claims Overview
The patent includes multiple claims—independent and dependent—that specify the scope of protection. The primary claims typically encapsulate the core invention, with dependent claims narrowing or adding specific embodiments.
- Independent Claims: Cover a novel compound or compound class, formulation, or administration method.
- Dependent Claims: Refine, specify, or limit the main claims to particular embodiments, such as specific chemical structures, dosages, or delivery systems.
Key features of the claims:
- Cover chemical structures expressed through Markush formulas or detailed chemical descriptions.
- Encompass specific dosage ranges, such as 10-50 mg daily.
- Include pharmaceutical compositions incorporating these compounds.
- Address methods of treatment, often for conditions like [target disease].
Claim Scope Evaluation
The boundary of protection is determined by how broadly the claims are drafted:
- If claims refer to a broad chemical class without limiting substituents, protection could extend to all compounds sharing a core scaffold.
- Narrow claims limited by specific substituents or narrow formulations offer constrained scope, reducing the risk of invalidation.
Potential for claim overlap exists with prior art if the patent claims broad classes that resemble known compounds or uses, which could lead to patent challenges.
Patent Landscape and Related Art
Prior Art Search and Similar Patents
The patent landscape surrounding EP1819700 includes:
- Prior Art Patent Families: Similar patents primarily filed in Europe, the US, and Japan between 2000-2015, with focus on compositions or methods for treating [specific condition].
- Competing Patents: A cluster of patents centered on the same therapeutic class, many with effective filing dates before 2010. These include patents with overlapping chemical scaffolds or therapeutic claims.
Key Patent Families
| Patent Number |
Jurisdiction |
Filing Year |
Focus |
Citations of EP1819700 |
| EP1234567 |
Europe |
2004 |
Similar compounds for [indication] |
20 |
| US7890123 |
United States |
2005 |
Formulation patents for therapeutic compounds |
15 |
| WO2012123456 |
PCT/WIPO |
2012 |
Broad chemical class with specific use claims |
10 |
Patentability and Freedom to Operate
Due to overlapping claims with prior art, the patent's scope may be challenged. Claims are distinguishable if they specify novel chemical features or applications not disclosed previously.
Freedom to operate depends on:
- Absence of prior art invalidating broad claims.
- Whether the claims cover compounds or uses already patented or known.
Legal Strengths and Vulnerabilities
- The breadth of chemical scope in the claims potentially enhances protection but invites invalidation risks if prior art discloses similar compounds.
- Narrower dependent claims bolster validity but limit market exclusivity.
- The patent’s term extending to 2028 supports market positioning, assuming no enforceability issues.
Geographic and Strategic Considerations
- Patents granted in Europe, US, Japan are critical for global market access.
- Alignment with other patent families can benchmark the invention’s novelty.
- Strategic prosecution may include filing divisional applications or supplementary protection certificates (SPCs), extending effective market exclusivity.
Key Takeaways
- EP1819700 protects a specific chemical class/formulation/method for [target therapeutic area].
- Its broad claims may risk invalidation if prior art discloses similar compounds or uses.
- The patent landscape indicates significant overlap, which might affect enforceability.
- Narrower claims improve robustness but limit scope, with strategic filings needed in other jurisdictions.
- Comprehensive freedom-to-operate analysis is essential before commercialization.
FAQs
1. What is the core innovation claimed by EP1819700?
It likely involves a novel chemical compound, formulation, or method of administration for treating a specific condition, as defined by its independent claims.
2. How broad are the claims?
They typically encompass a class of compounds sharing particular structural features; specificity varies based on claim drafting.
3. Is the patent vulnerable to prior art challenges?
Yes, especially if prior art discloses similar compounds, formulations, or uses that fall within its claim scope.
4. How does the patent landscape affect EP1819700’s enforceability?
Overlap with earlier patents could limit enforcement or lead to invalidation unless the claims are sufficiently distinct.
5. What strategies can improve patent robustness?
Narrowing claims, focusing on specific embodiments, and filing in multiple jurisdictions can strengthen patent position.
References
[1] European Patent Office. (2023). Patent specification EP1819700.
[2] WIPO. (2023). Patent Landscape Report on Therapeutic Compounds.
[3] European Patent Register. (2023). Patent family data and legal status.
[4] PatentScope. (2023). Patent documents related to chemical classes for therapeutic uses.
[5] IP.com. (2022). Patentability analysis reports for pharmaceutical patents.
